Physician profile
Premetesh Chattoo
NPI 1255395083
$171,104.12
in general payments reported to CMS, 2019-2025
28 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $14K · 2021: $26K · 2022: $27K · 2023: $21K · 2024: $47K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Travel and Lodging: $13K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,585.00 |
| Travel and Lodging | $12,585.56 |
| Food and Beverage | $11,327.06 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,425.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $71,869.49 | 2019-2024 | Epclusa |
| Phathom Pharmaceuticals, INC. | $34,881.57 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30,855.09 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Abbvie INC. | $17,712.40 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Allergan, INC. | $5,256.83 | 2019-2020 | |
| Redhill Biopharma INC. | $3,998.06 | 2020-2025 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $3,000.98 | 2021-2024 | Linzess |
| Madrigal Pharmaceuticals | $1,032.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $693.80 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $319.85 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $285.44 | 2024-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $250.92 | 2021 | |
| Merck Sharp & Dohme LLC | $182.26 | 2022-2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $145.03 | 2019-2025 | Entyvio |
| Braintree Laboratories, INC. | $133.57 | 2021-2024 | Suflave |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $106.71 | 2019-2020 | |
| Horizon Therapeutics Plc | $87.46 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $79.43 | 2020-2022 | |
| Intra-Sana Laboratories | $30.77 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Daiichi Sankyo INC. | $30.53 | 2021 | |
| Novo Nordisk INC | $27.28 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $24.79 | 2019 | |
| Lilly USA, LLC | $23.08 | 2025 | Omvoh |
| Medtronic, INC. | $18.97 | 2023 | Gi Genius |
| Janssen Biotech, INC. | $18.76 | 2024 | Stelara |
| Pfizer INC. | $13.30 | 2020 | |
| Intercept Pharmaceuticals, INC. | $12.56 | 2021 | |
| Alfasigma USA, INC. | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Premetesh Chattoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.